H. Lundbeck, Ebixa® approved in Canada for the treatment of Alzheimer’s disease

Lundbeck’s Ebixa® (memantine) has been approved by the Canadian health authorities – Health Canada - for the treatment of moderate to severe Alzheimer’s disease. Ebixa® is expected to be on the market in Canada before the end of the year.